Keyword: Neurocrine Biosciences
Spruce's lead drug reduced the level of three hormones overproduced by patients with congenital adrenal hyperplasia, teeing it up for its next trial.
Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.
Two years after it walked away from a Voyager Therapeutics-partnered Parkinson’s gene therapy, Sanofi Genzyme is at it again.
The drug comfortably beat placebo against a slew of efficacy endpoints and posted comparable safety and tolerability to the control.
Neurocrine Biosciences' congenital adrenal hyperplasia treatment significantly lowered levels of two types of hormones in most patients.
The deal sees Neurocrine commit to $1.7 billion in milestones in return for Parkinson’s disease program VY-AADC and other assets.
The collaboration gives Neurocrine a potential source of small molecules to treat disorders of the central nervous system.
The FDA will make its decision on AbbVie's elagolix to Q3, as it needs more time to review liver function tests.
Novartis poached Pfizer oncology head Liz Barrett, Ed Kaye became Stoke Therapeutics' CEO, and Perrigo hired Uwe Röhrhoff as CEO.
Neurocrine Biosciences has published a journal paper about its phase 3 trial of tardive dyskinesia candidate Ingrezza.
